4. Peppard PE,Young T,Palta M,et al. Prospective study of the association between sleep-disordered breathing and hypertension. N Engl J Med,2000,342:1378-1384.
[2]
7. Lloberes P,Lozano L,Sampol G,et al. Obstructive sleep apnoea and 24-h blood pressure in patients with resistant hypertension. J Sleep Res,2010,19:597-602.
[3]
8. Bradley TD,Floras JS. Obstructive sleep apnoea and its cardiovascular consequences. Lancet,2009,373:82-93.
[4]
12. Mcnicholas WT. Chronic obstructive pulmonary disease and obstructive sleep apnea:overlaps in pathophysiology,systemic inflammation,and cardiovascular disease. Am J Respir Crit Care Med,2009,180:692-700.
[5]
13. Schmieder RE,Redon J,Grassi G,et al. ESH position paper:renal denervation-an interventional therapy of resistant hypertension. J Hypertens,2012,30:837-841.
[6]
14. Krum H,Schlaich M,Whitbourn R,et al. Catheter-based renal sympathetic denervation for resistant hypertension:a multicentre safety and proof-of-principle cohort study. Lancet,2009,373:1275-1281.
[7]
15. Esler MD,Krum H,Sobotka PA,et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial):a randomised controlled trial. Lancet,2010,376:1903-1909.
[8]
16. Symplicity HTN-1 Investigators. Catheter-based renal sympathetic denervation for resistant hypertension:durability of blood pressure reduction out to 24 months. Hypertension,2011,57:911-917.
[9]
18. Esler MD,Bohm M,Sievert H,et al. Catheter-based renal denervation for treatment of patients with treatment-resistant hypertension:36 month results from the SYMPLICITY HTN-2 randomized clinical trial. Eur Heart J,2014,35:1752-1759.
[10]
20. B？hm M. Medtronic Global SYMPLICITY Registry Shows Strong Safety Profile of the Symplicity(TM) Renal Denervation System. Six-Month Analysis of First 1,000 Patients Enrolled in Real-World Patient Registry;Proceedings of American College of Cardiology 2014 scientific sessions. Washington:cardio source,DC,USA,2014:29-31.
1. ？Calhoun DA,Jones D,Textor S,et al. Resistant hypertension:diagnosis,evaluation,and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension,2008,51:1403-1419.
3. Witkowski A,Prejbisz A,Florczak E,et al. Effects of renal sympathetic denervation on blood pressure,sleep apnea course,and glycemic control in patients with resistant hypertension and sleep apnea. Hypertension,2011,58:559-565.
10. Gjorup PH,Sadauskiene L,Wessels J,et al. Abnormally increased endothelin-1 in plasma during the night in obstructive sleep apnea:relation to blood pressure and severity of disease. Am J Hypertens,2007,20:44-52.
[22]
11. Clark DR,Ahmed MI,Calhoun DA. Resistant hypertension and aldosterone:an update. Can J Cardiol,2012,28:318-325.
[23]
17. Krum H,Schlaich MP,Sobotka PA,et al. Percutaneous renal denervation in patients with treatment-resistant hypertension:final 3-year report of the Symplicity HTN-1 study. Lancet,2014,383:622-629.
[24]
19. Bhatt DL,Kandzari DE,O’Neill WW,et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med,2014,370:1393-1401.
[25]
21. Shantha GP,Pancholy SB. Effect of renal sympathetic denervation on apnea-hypopnea index in patients with obstructive sleep apnea:a systematic review and meta-analysis. Sleep Breath,2015,19:29-34.
[26]
23. Yumino D,Redolfi S,Ruttanaumpawan P,et al. Nocturnal rostral fluid shift:a unifying concept for the pathogenesis of obstructive and central sleep apnea in men with heart failure. Circulation,2010,121:1598-1605.
[27]
25. Koistinen HA,Zierath JR. Regulation of glucose transport in human skeletal muscle. Ann Med,2002,34:410-418.
